Understanding Local, Thinking Local, Being Local The biopharmaceutical industry stands at a crossroads with its very future in question. The problem is deep-seated, arising from serious structural flaws in the way the industry has been constructed. Incremental...
Asia is rapidly becoming a new frontier for drug development as Western companies seek to develop and register their products in Asia, while emerging Asian companies seek new capabilities to globalize products. As Asia continues to grow, the need for improved...
Doubled over the past decade, while new drug approvals have dropped down to a third. With the R&D cost now at more than US $1.2 billion per drug approved, only one in five drugs approved is able to pay for the cost of its own development. As health agencies become...
